30/03/2022
Galecto Completes Enrollment in Phase 1b_2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis BOSTON, March 29, 2022 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the...
08/03/2022
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets NEC OncoImmunity (NOI), a subsidiary of NEC Corporation (NEC), and VAXIMM AG, a Swiss/German biotech company focused on developing an oral plug and play DNA vaccination technology to stimulate...
We use cookies on the website sunstone.eu in order to generate statistics and to maximize user-friendliness and improve functionality. By using our website, you consent to our use of cookies. Click on cookie settings below if you wish to disable cookies. Or you can read more about what cookies are, how we use them and how you disable cookies Here.
Cookie settingsAccept Privacy & Cookies Policy
Recent Comments